ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticalsits history only182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatrisits history only130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose USits history only101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharmaits history only60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead
HALEON11 open or runningphase 4since Aug 31, 2026Aug 31, 2026Dec 2026phase 4 · NCT07817134

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of HALEON only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2026First study: phase 4 study in Rhinitis, Allergic, PerennialFirst studyNCT07817134 · 16 planned · Canada

Ahead

  1. Dec 2026Primary completion: phase 4 study in Rhinitis, Allergic, PerennialNCT07817134

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study HALEON leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07817134Rhinitis, Allergic, Perennial · Canada4Not yet recruitingDec 202616

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.